news flash·2025-05-21 08:15Core Viewpoint - The approval of Tafasitamab (brand name: Mingnuokai) in combination with Lenalidomide for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (r/rDLBCL) marks a significant milestone as it is the first CD19 monoclonal antibody approved for this indication in China [1] Company Summary - The company, Innovent Biologics, has received approval from the National Medical Products Administration (NMPA) for its CD19-targeting product Tafasitamab [1] - This approval highlights the company's commitment to addressing unmet medical needs in oncology [1] Industry Summary - The approval of Tafasitamab represents a breakthrough in the treatment landscape for r/rDLBCL in China, potentially improving outcomes for patients who are not suitable for autologous stem cell transplantation [1] - The introduction of this therapy may enhance competition in the oncology market, particularly in the segment of targeted therapies for hematological malignancies [1]